N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propynyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide | 370553-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propynyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide
• 英文别名: N-[(4-chlorophenyl)methyl]-8-[3-(1,1-dioxo-1,4-thiazinan-4-yl)prop-1-ynyl]-6-(morpholin-4-ylmethyl)-4-oxo-1H-cinnoline-3-carboxamide
• CAS: 370553-71-2
• 化学式: C₂₈H₃₀ClN₅O₅S
• 分子量: 584.096
• InChiKey: CZQMZCJDLBGTKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1243271A1

  公开（公告）日：2002-09-25

  A nose drop containing the compound (I) represented by the formula wherein Ar1 and Ar2 are each an aromatic group, Ar1 and Ar2 optionally form a condensed cyclic group together with the adjacent carbon atom, ring B is a nitrogen-containing heterocycle, X and Y are each a bond, an oxygen atom or S(O)p (p is 0 to 2), NR4 (R4 is H or a lower alkyl group) or a divalent linear lower hydrocarbon group optionally having substituents and containing 1 to 3 heteroatoms, A is N or CR7 (R7 is H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents), R1, R2 and R3 are each H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents, and R8 is H, a hydroxy group optionally substituted by a lower alkyl group or a carboxyl group, provided that the nitrogen-containing heterocycle represented by ring B is not a heterocycle represented by the formula wherein n is 0 - 1, or a salt thereof or a prodrug thereof, exhibits a superior prophylactic or therapeutic effect on allergic rhinitis and the like.

  一种含有由以下公式表示的化合物（I）的鼻滴 其中Ar1和Ar2各自是芳香基团，Ar1和Ar2可以与相邻的碳原子一起形成紧凑的环状基团，环B是含氮杂环，X和Y各自是键，氧原子或S（O）p（p为0至2），NR4（R4为H或低碳基团）或二价线性低碳氢基团，可选地具有取代基并含有1至3个杂原子，A为N或CR7（R7为H、卤素原子、碳氢基团、酰基或可选地具有取代基的羟基），R1、R2和R3各自为H、卤素原子、碳氢基团、酰基或可选地具有取代基的羟基，以及 R8为H、可选地由低碳基团或羧基取代的羟基，前提是由环B表示的含氮杂环不是由以下公式表示的杂环 其中n为0-1，或其盐或前药，对过敏性鼻炎等表现出卓越的预防或治疗作用。
• 4-hydroxycinnoline-3-carboxyamides as antiviral agents
  申请人：——

  公开号：US20020042397A1

  公开（公告）日：2002-04-11

  Certain novel 4-hydroxycinnoline-3-carboxyamides. The compounds are particularly effective in the treatment or prevention of viral infections, particularly infections caused by herpes viruses including herpes simplex virus types 1 and 2, human herpes virus types 6, 7 and 8, varicello zoster virus, human cytomegalovirus or Epstein-Barr virus.

  某些新型4-羟基肉桂酰胺基喹啉化合物。这些化合物在治疗或预防病毒感染方面特别有效，尤其是对由疱疹病毒引起的感染，包括单纯疱疹病毒类型1和2、人类疱疹病毒类型6、7和8、水痘-带状疱疹病毒、人类巨细胞病毒或EB病毒感染。
• Method of preventing or treating atherosclerosis or restenosis
  申请人：——

  公开号：US20040067947A1

  公开（公告）日：2004-04-08

  The present invention provides a method of preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a compound selected from the group consisting of structures of Formulas VI, VII, VIII and IX: 1 wherein the various groups in the Formulae are as defined herein.

  本发明提供了一种预防或治疗哺乳动物动脉粥样硬化或再狭窄的方法，该方法包括施用有效量的选自由式VI、VII、VIII和IX的结构组成的组的化合物： 1 其中式中各基团如本文所定义。
• 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1265872A1

  公开（公告）日：2002-12-18
• US6458788B1
  申请人：——

  公开号：US6458788B1

  公开（公告）日：2002-10-01